---
schema_version: "secwatch.filing_event.v1"
accession: "0001606498-26-000002"
form_type: "8-K"
ticker: "AVNS"
cik: "0001606498"
company_name: "AVANOS MEDICAL, INC."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:48:41.721269+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Avanos reports Q4 adjusted EPS $0.29 vs $0.43 prior year; FY2025 sales $701.2M up 1.9%

## Summary
- Q4 net sales $180.9M (+0.7% YoY); SNS segment up 8.7% to $115.1M; PM&R up 1.3% to $61.6M.
- Q4 GAAP net loss $1.3M ($0.03 loss per share); adjusted net income $13.4M ($0.29 adjusted EPS).
- Full-year 2025 net loss $72.9M; adjusted EBITDA $86.8M vs $107.6M in 2024.
- Recorded $77M non-cash goodwill impairment on PM&R segment in Q2 2025.
- 2026 guidance: net sales $700-720M; adjusted diluted EPS $0.90-1.10.

## SEC filing metadata
- accession: 0001606498-26-000002
- form_type: 8-K
- ticker: AVNS
- cik: 0001606498
- company_name: AVANOS MEDICAL, INC.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1606498/000160649826000002/0001606498-26-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1606498/000160649826000002/avns-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001606498-26-000002
- JSON: https://secwatch.observer/filing/0001606498-26-000002.json
- Plain text: https://secwatch.observer/filing/0001606498-26-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.